Understanding of MoA can be very important for FDA approval ( particularly where advisory committees are convened for an approval ). So potential partners or buyers will be keen to see that this understanding of MoA is being developed.
For First In Class treatments it’s probably even more important.
Biomarkers of treatment response are in my view part and parcel of understanding MoA.
Ann: New Collaboration to Understand Zantrene Cardioprotection, page-18
-
- There are more pages in this discussion • 71 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.79 |
Change
0.010(0.56%) |
Mkt cap ! $304.2M | |||
| Open | High | Low | Value | Volume |
| $1.78 | $1.80 | $1.78 | $106.4K | 59.41K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 600 | $1.78 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.83 | 10000 | 2 |
View Market Depth
| Last trade - 15.57pm 30/09/2024 (20 minute delay) ? |
| RAC (ASX) Chart |